Table 6.
Previously discovered monoclonal antibodies for SARS-CoV.
| Monoclonal antibody | Mechanism of action |
|---|---|
| 80R | Binds S1 and prevents interaction with ACE-2 (158) |
| CR3014 CR3022 |
Synergistic action; bind S1 and prevent interaction with ACE-2; prevent immune escape (159, 160) |
| F26G18 F26G19 M396 |
Bind linear epitope of S1; Bind conformational epitope of S1; Inhibit interaction of S1 with ACE-2 (161) |
| 1A9 | Binds HDR domain of S2 and prevents interaction of receptor in vitro (162) |
| 201 | Binds S1 and prevents interaction with ACE-2 (163) |
| Monoclonal antibodies studied for the treatment of SARS-CoV-2 | Function |
| LY-CoV555 | IgG that binds to a conserved region in the RBD of the S protein and fully neutralizes SARS-CoV and SARS-CoV-2 (129) [NCT04411628] [NCT04427501] |
| Anti-C5a antibody | Prevents cytokine-mediated lung damage (85, 127) |
| Hrs-ACE-2 (APN01) | ACE-2-receptor decoy preventing infection (130, 131) [NCT04335136] |
| Tocilizumab | IL-6 antagonist that binds both sIL-6 and mIL-6 thus preventing cytokine storm (136, 138) |
| Convalescent plasma | Preformed IgG harvested from cured patients (148, 149) |
| Bevacizumab | Targets VEGF, preventing vascular barrier permeability thus inhibiting the development of ARDS [NCT04275414] (128) |
| Anakinra | IL-1-inhibitor used to reduce effects of the cytokine storm in SARS-CoV-2 (143) |